A Phase 2 interventional study of GSK2140944 in Gonorrhea, sponsored by GlaxoSmithKline. Completed at 14 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-05-23.
Sponsored by GlaxoSmithKline · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 98 studies in Gonorrhea with a site in United States — 11 open to participants now, 11 under way, none of them phase 3. Gonorrhea · United States.
Among the 98 studies in Gonorrhea with a site in United States, this one is the 50th largest by enrollment of the 76 interventional ones that give a count, is one of 4 that started in 2015, is one of 11 in phase 2, and was the 40th registered.
168 studies on the registry are indexed under Gonorrhea; 32 are open to participants now.
Browse Gonorrhea studies →11 of the 98 studies in Gonorrhea with a site in United States are open now. Recruiting first, the newest first:
Emory University · Sites in United States
Women only · Healthy volunteers
Westat · Sites in United States
Ages 13–29 · Women only
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 16–24
Tulane University · Sites in United States
Ages 15–26 · Healthy volunteers
Queen's Medical Center · Sites in United States
Ages 14+ · Women only · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 18 Gonorrhea studies recruiting now, 11 (61%) set no upper age limit and 6 (33%) stop at 75 or younger; 10 take children under 18; 12 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
98 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 14 · Phase 3 11 · Phase 4 7
First in 1999; this study’s year is marked. 4 started in 2015.
This study's enrollment of 106 is below the median of 380 across 126 interventional studies indexed under Gonorrhea.
Median enrollment 341 across the 76 interventional studies, 907 across the 21 observational. Of the 85 that completed or were terminated, 37 (44%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 98 have an industry lead sponsor. The 10 most frequent:
GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.
Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.
GlaxoSmithKline has 2 studies filed under Gonorrhea — fewer than ten, so there is no comparison to draw.
1 of the studies in Gonorrhea with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06844045Icahn School of Medicine at Mount SinaiPoint of Care STI Testing | 2026-12-31 |
Add it to your calendar (.ics) → With an account.
Among the 98 studies in Gonorrhea with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
GSK2140944 has demonstrated in vitro activity against Neisseria (N.) gonorrhoeae, including ciprofloxacin resistant and susceptible strains. This study is a Phase II, randomized, multicenter, open-label, dose ranging study designed to inform the optimal oral dose of GSK2140944 by further characterizing the efficacy, safety, and tolerability in subjects with uncomplicated urogenital gonorrhea due to N. gonorrhoeae. Subjects will be randomly assigned to receive either a single 1500 milligrams (mg) or 3000 mg oral dose of GSK2140944. Appropriate safety and microbiological assessments will be conducted at the Baseline (Day 1) Visit and repeated at the Test-of-Cure (Day 4 to 8) Visit. The study duration will be approximately 1 week. Approximately 60 microbiologically evaluable subjects (30 subjects in each treatment arm) will complete the study if both arms remain active throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
The subject is an adult male or female at least 18 years of age at the time of signing who meets one of the following criteria:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive single oral dose of GSK2140944 1500 mg.
Drug: GSK2140944
Subjects will receive single oral dose of GSK2140944 3000 mg.
Drug: GSK2140944
Immediate release capsules (pink hard gelatin size 00 capsule, with no external marking, filled with slightly agglomerated pale yellowish to grayish yellow powder) containing GSK2140944 500 mg and inactive formulation excipients. GSK2140944 will be administered orally once 1500 mg (3 capsules) or 3000 mg (6 capsules).
Number of Participants With Culture-confirmed Bacterial Eradication of Urogenital Neisseria Gonorrhoeae at the Test-of-Cure Visit
Pre-treatment urogenital, pharyngeal, and rectal swab specimens were obtained for bacteriological culture for neisseria (N.) gonorrhoeae at the Baseline visit. Test- of-Cure was defined by infection site (that is urogenital and, as appropriate, rectal and/or pharyngeal) as culture confirmed bacterial eradication of N. gonorrhoeae observed 3 to 7 days post-treatment. Pre-treatment urogenital specimens were obtained for nucleic acid amplification test (NAAT) assay to detect the presence of N. gonorrhoeae and chlamydia trachomatis at the Baseline visit. Only participants who had a pre-therapy N. gonorrhoeae isolate recovered from their urogenital specimen were evaluated. Microbiologically evaluable (ME) Population comprised of all randomized participants who had N. gonorrhoeae isolated from Baseline cultures of urogenital swab specimens, received any dose of gepotidacin, and returned for their TOC visit.
Time frame: Baseline (Day 1, pre-dose) and Test-of-Cure visit (Day 4 to 8)
Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)
An AE is any untoward medical occurrence in a clinical investigation participants, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinaemia (defined as alanine aminotransferase \[ALT\] \>=3 times upper limit of normal \[ULN\] and bilirubin \>=2 times ULN \[\>35 percent direct\] \[or ALT \>=3 times ULN and international normalization ratio INR\>1.5, if INR is measured\].
Time frame: From start of the study treatment until Test-of-Cure visit (Day 4 to 8)
Change From Baseline in Systolic and Diastolic Blood Pressure (BP) at the Indicated Time Points
BP was measured in semi-supine position after 5 minutes rest. It was recorded at Baseline visit, 2 hour post-dose visit for participants enrolled under orignal protocol, 0.5 hour post-dose for participants enrolled under protocol amendement 1 and up to TOC visit (Day 4 to 8).Vital sign measurements were obtained prior to any scheduled blood collection visit on the same assessment day. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as TOC visit value minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline visit (Day 1) and Day 4 to Day 8
Change From Baseline in Pulse Rate at the Indicated Time Points
Pulse rate was measured in semi-supine position after 5 minutes rest. It was recorded at Baseline visit, 2 hour post-dose visit for participants enrolled under orignal protocol, 0.5 hour post-dose for participants enrolled under protocol amendement 1 and up to TOC visit (Day 4 to 8). Vital sign measurements were obtained prior to any scheduled blood collection visit on the same assessment day. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as TOC visit value minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline visit (Day 1) and Day 4 to Day 8
Change From Baseline in Temperature at the Indicated Time Points
Temperature was measured in semi-supine position after 5 minutes rest. It was recorded at Baseline visit, 2 hour post-dose visit for participants enrolled under orignal protocol, 0.5 hour post-dose for participants enrolled under protocol amendement 1 and up to TOC visit (Day 4 to 8). Vital sign measurements were obtained prior to any scheduled blood collection visit on the same assessment day. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as TOC visit value minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline visit (Day 1) and Day 4 to Day 8
Change From Baseline in Respiratory Rate at the Indicated Time Points
Respiratory rate was measured in semi-supine position after 5 minutes rest. It was recorded at Baseline visit, 2 hour post-dose visit for participants enrolled under orignal protocol, 0.5 hour post-dose for participants enrolled under protocol amendement 1 and up to TOC visit (Day 4 to 8). Vital sign measurements was obtained prior to any scheduled blood collection visit on the same assessment day. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as TOC Visit value minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline visit (Day 1) and Day 4 to Day 8
Number of Participants With Abnormal Electrocardiogram (ECG) Findings
A single 12-lead ECGs were obtained at the Baseline, 2 hour post-dose, and at the TOC (Day 4 to 8) visit using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT (QTc) intervals. ECG was obtained prior to any vital sign measurements or blood draws scheduled on the same assessment day. For participants enrolled under protocol amendment 1, ECG was measured at Baseline visit Day 1 (pre-dose) only. ECG assessments were presented as abnormal-clinically significant (CS) and abnormal-not clinically significant (NCS) at the indicated time points. Only those participants available at the specified time points were analyzed (represented by n=X , X in the category titles).
Time frame: Baseline visit and up to Day 8
Number of Participants With Abnormal Physical Examination Finding
Physical examination of respiratory, cardiovascular, abdomen, gastrointestinal, urogenital systems, pharyngeal and rectal examinations with collections of microbiology specimen was performed at the Baseline and TOC (Day 4 to 8) visit. Baseline was defined as the study assessment on Day 1 (pre-dose). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline visit and Test-of-Cure visit (Day 4 to 8)
Change From Baseline in Hemoglobin, Protein and Albumin at Test-of-Cure Visit (Day 4 to 8)
Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate hemoglobin, total protein and albumin. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline visit and Test-of-Cure visit (Day 4 to 8)
Change From Baseline in Hematocrit at Test-of-Cure Visit (Day 4 to 8)
Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate hematocrit. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline visit and Test-of-Cure visit (Day 4 to 8)
Change From Baseline in Lymphocyte, Monocyte, Neutrophil Basophil, Eosinophil, Leukocyte and Platelet Count at Test-of-Cure Visit (Day 4 to 8)
Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate neutrophil, lymphocyte, basophil, eosinophil, monocyte, leukocyte and platelet count. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline visit and Test-of-Cure visit (Day 4 to 8)
Change From Baseline in Bilirubin, Direct Bilirubin and Creatinine at Test-of-Cure Visit (Day 4 to 8)
Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate bilirubin, direct bilirubin and creatinine. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline visit and Test-of-Cure visit (Day 4 to 8)
Change From Baseline in Alanine Aminotransferase, Aspartate Aminotransferase and Alkaline Phosphatase at Test-of-Cure Visit (Day 4 to 8)
Blood samples were collected at Baseline Day 1.(pre-dose) and at TOC visit (Day 4 to 8) to evaluate alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline visit and Test-of-Cure visit (Day 4 to 8)
Change From Baseline in Chloride, Calcium, Glucose, Potassium, Sodium and Urea at Test-of-Cure Visit (Day 4 to 8)
Blood samples were collected at Baseline Day 1.(pre-dose) and at TOC visit (Day 4 to 8) to evaluate chloride, calcium, glucose, potassium, sodium and urea (blood urea nitrogen). Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline visit and Test-of-Cure visit (Day 4 to 8)
Change From Baseline in Erythrocytes at Test-of-Cure Visit (Day 4 to 8)
Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate erythrocytes (red blood cell count). Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline visit and Test-of-Cure visit (Day 4 to 8)
Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin at Test-of-Cure Visit (Day 4 to 8)
Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate erythrocytes mean corpuscular hemoglobin. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC Visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline visit and Test-of-Cure visit (Day 4 to 8)
Change From Baseline in Erythrocytes Mean Corpuscular Volume at Test-of-Cure Visit (Day 4 to 8)
Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate erythrocytes mean corpuscular volume. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC Visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline visit and Test-of-Cure visit (Day 4 to 8)
Number of Participants With Abnormal Urinalysis Dipstick Results
Dipstick urinalysis was done for glucose, ketones, occult blood, protein, potential hydrogen (pH) and specific gravity at Baseline visit Day 1 (pre-dose) and Test-of-Cure visit (Day 4 to 8). Results were presented as negative (normal) or other findings reported only if observed under microscopic examination trace, 1+, 2+, 3+, 4+ and 5+ glucose, ketones, occult blood and protein. pH results were categorized as per their pH values. Baseline was defined as the study assessment on Day 1 (pre-dose). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
Time frame: Baseline visit and Test-of-Cure visit (Day 4 to 8)
This was a phase II, randomized, multicenter, open-label, dose ranging study evaluating the efficacy, safety and tolerability of gepotidacin therapy in participants with uncomplicated urogenital gonorrhea. The study duration was approximately 1 week with 2 planned study visits: Baseline (Day 1, pre-dose) and Test-of-Cure (TOC) (Day 4 to 8) visit.
| Milestone | GSK2140944 1500 mg | GSK2140944 3000 mg |
|---|---|---|
| Started | 53 | 53 |
| Completed | 52 | 53 |
| Not completed | 1 | 0 |
| Withdrew: Could not swallow pills | 1 | 0 |
Pre-treatment urogenital, pharyngeal, and rectal swab specimens were obtained for bacteriological culture for neisseria (N.) gonorrhoeae at the Baseline visit. Test- of-Cure was defined by infection site (that is urogenital and, as appropriate, rectal and/or pharyngeal) as culture confirmed bacterial eradication of N. gonorrhoeae observed 3 to 7 days post-treatment. Pre-treatment urogenital specimens were obtained for nucleic acid amplification test (NAAT) assay to detect the presence of N. gonorrhoeae and chlamydia trachomatis at the Baseline visit. Only participants who had a pre-therapy N. gonorrhoeae isolate recovered from their urogenital specimen were evaluated. Microbiologically evaluable (ME) Population comprised of all randomized participants who had N. gonorrhoeae isolated from Baseline cultures of urogenital swab specimens, received any dose of gepotidacin, and returned for their TOC visit.
| Participants | GSK2140944 1500 mg | GSK2140944 3000 mg |
|---|---|---|
| Number of Participants With Culture-confirmed Bacterial Eradication of Urogenital Neisseria Gonorrhoeae at the Test-of-Cure Visit | 29 | 37 |
An AE is any untoward medical occurrence in a clinical investigation participants, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. SAE is any untoward event resulting in death, life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, congenital anomaly/birth defect, any other situation according to medical or scientific judgment or all events of possible drug-induced liver injury with hyperbilirubinaemia (defined as alanine aminotransferase \[ALT\] \>=3 times upper limit of normal \[ULN\] and bilirubin \>=2 times ULN \[\>35 percent direct\] \[or ALT \>=3 times ULN and international normalization ratio INR\>1.5, if INR is measured\].
| Participants | GSK2140944 1500 mg | GSK2140944 3000 mg |
|---|---|---|
| Any AE | 27 | 34 |
| Any SAE | 0 | 0 |
BP was measured in semi-supine position after 5 minutes rest. It was recorded at Baseline visit, 2 hour post-dose visit for participants enrolled under orignal protocol, 0.5 hour post-dose for participants enrolled under protocol amendement 1 and up to TOC visit (Day 4 to 8).Vital sign measurements were obtained prior to any scheduled blood collection visit on the same assessment day. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as TOC visit value minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Millimeter of mercury (mmHg) | GSK2140944 1500 mg | GSK2140944 3000 mg |
|---|---|---|
| Systolic BP, Day 1, 2 hr post-dose, n=47, 48 | 0.4 ± 11.61 | 1.3 ± 11.97 |
| Systolic BP, Day 4 to 8, n=52, 53 | -2.8 ± 13.11 | 0.5 ± 11.73 |
| Diastolic BP, Day 1, 2 hr post-dose, n=47, 48 | 0.1 ± 7.61 | -0.9 ± 8.40 |
| Diastolic BP, Day 4 to 8, n=52, 53 | -2.3 ± 8.73 | -2.2 ± 9.86 |
Pulse rate was measured in semi-supine position after 5 minutes rest. It was recorded at Baseline visit, 2 hour post-dose visit for participants enrolled under orignal protocol, 0.5 hour post-dose for participants enrolled under protocol amendement 1 and up to TOC visit (Day 4 to 8). Vital sign measurements were obtained prior to any scheduled blood collection visit on the same assessment day. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as TOC visit value minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Beats per minute | GSK2140944 1500 mg | GSK2140944 3000 mg |
|---|---|---|
| Pulse rate Day 1, 2 hr post-dose, n=47, 48 | -0.3 ± 12.20 | -1.4 ± 8.72 |
| Pulse rate, Day 4 to 8, n=52, 53 | 1.1 ± 11.92 | 2.2 ± 14.12 |
Temperature was measured in semi-supine position after 5 minutes rest. It was recorded at Baseline visit, 2 hour post-dose visit for participants enrolled under orignal protocol, 0.5 hour post-dose for participants enrolled under protocol amendement 1 and up to TOC visit (Day 4 to 8). Vital sign measurements were obtained prior to any scheduled blood collection visit on the same assessment day. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as TOC visit value minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Celsius | GSK2140944 1500 mg | GSK2140944 3000 mg |
|---|---|---|
| Temperature, Day 1, 2 hr post-dose, n=47, 48 | -0.126 ± 0.4327 | -0.052 ± 0.3664 |
| Temperature, Day 4 to 8, n=52, 53 | -0.121 ± 0.4953 | -0.088 ± 0.3742 |
Respiratory rate was measured in semi-supine position after 5 minutes rest. It was recorded at Baseline visit, 2 hour post-dose visit for participants enrolled under orignal protocol, 0.5 hour post-dose for participants enrolled under protocol amendement 1 and up to TOC visit (Day 4 to 8). Vital sign measurements was obtained prior to any scheduled blood collection visit on the same assessment day. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as TOC Visit value minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Breaths per minute | GSK2140944 1500 mg | GSK2140944 3000 mg |
|---|---|---|
| Respiratory rate, Day 1, 2 hr post-dose, n=47, 48 | -0.1 ± 1.39 | -0.3 ± 1.51 |
| Respiratory rate, Day 4 to 8, n=52, 53 | 0.1 ± 1.66 | -0.1 ± 1.61 |
A single 12-lead ECGs were obtained at the Baseline, 2 hour post-dose, and at the TOC (Day 4 to 8) visit using an ECG machine that automatically calculates the heart rate and measures PR, QRS, QT, and corrected QT (QTc) intervals. ECG was obtained prior to any vital sign measurements or blood draws scheduled on the same assessment day. For participants enrolled under protocol amendment 1, ECG was measured at Baseline visit Day 1 (pre-dose) only. ECG assessments were presented as abnormal-clinically significant (CS) and abnormal-not clinically significant (NCS) at the indicated time points. Only those participants available at the specified time points were analyzed (represented by n=X , X in the category titles).
| Participants | GSK2140944 1500 mg | GSK2140944 3000 mg |
|---|---|---|
| Abnormal-NCS, pre-dose Day 1, n=52, 53 | 14 | 12 |
| Abnormal-CS, pre-dose Day 1, n=52, 53 | 0 | 0 |
| Abnormal-NCS, Day 1, 2 hr post, n=37, 36 | 8 | 9 |
| Abnormal-CS, Day 1, 2 hr post, n=37, 36 | 0 | 0 |
| Abnormal-NCS, Day 4 to 8, n=37, 35 | 7 | 11 |
| Abnormal-CS, Day 4 to 8, n=37, 35 | 0 | 0 |
Physical examination of respiratory, cardiovascular, abdomen, gastrointestinal, urogenital systems, pharyngeal and rectal examinations with collections of microbiology specimen was performed at the Baseline and TOC (Day 4 to 8) visit. Baseline was defined as the study assessment on Day 1 (pre-dose). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Participants | GSK2140944 1500 mg | GSK2140944 3000 mg |
|---|---|---|
| Abdomen, Baseline, n=50, 53 | 2 | 0 |
| Abdomen, TOC, n=51, 52 | 0 | 0 |
| Cardiovascular, Baseline, n=52, 53 | 1 | 1 |
| Cardiovascular, TOC, n=51, 53 | 0 | 0 |
| Gastrointestinal, Baseline, n=49, 52 | 1 | 0 |
| Gastrointestinal, TOC, n=50, 51 | 2 | 0 |
| Pharyngeal, Baseline, n=51, 51 | 1 | 4 |
| Pharyngeal, TOC, n=51, 52 | 0 | 0 |
| Rectal examination, Baseline, n=46, 46 | 2 | 4 |
| Rectal examination, TOC, n=41, 42 | 1 | 2 |
| Respiratory, Baseline, n=52, 53 | 1 | 0 |
| Respiratory, TOC, n=52, 53 | 0 | 0 |
| Urogenital, Baseline, n=52, 53 | 49 | 47 |
| Urogenital, TOC, n=52, 51 | 5 | 6 |
Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate hemoglobin, total protein and albumin. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Gram (G)/Liter (L) | GSK2140944 1500 mg | GSK2140944 3000 mg |
|---|---|---|
| Hemoglobin, n=46, 53 | -3.0 ± 6.89 | -3.9 ± 8.79 |
| Albumin, n=52, 53 | -0.5 ± 2.10 | -0.8 ± 2.51 |
| Protein, n=52, 53 | -1.1 ± 3.62 | -2.0 ± 4.01 |
Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate hematocrit. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Proportion of blood | GSK2140944 1500 mg | GSK2140944 3000 mg |
|---|---|---|
| Change From Baseline in Hematocrit at Test-of-Cure Visit (Day 4 to 8) | -0.0117 ± 0.02213 | -0.0155 ± 0.03166 |
Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate neutrophil, lymphocyte, basophil, eosinophil, monocyte, leukocyte and platelet count. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| 10^9 cells/L | GSK2140944 1500 mg | GSK2140944 3000 mg |
|---|---|---|
| Lymphocytes, n=46, 52 | 0.141 ± 0.5437 | 0.053 ± 0.6846 |
| Monocytes, n=46, 52 | -0.013 ± 0.1339 | 0.026 ± 0.1377 |
| Neutrophils , n=46, 52 | -0.834 ± 1.7564 | -0.598 ± 1.9185 |
| Platelets, n=45, 53 | 6.4 ± 35.63 | -5.8 ± 26.41 |
| Basophils, n=46, 52 | -0.001 ± 0.0146 | 0.002 ± 0.0155 |
| Eosinophils, n=46, 52 | 0.023 ± 0.1147 | 0.027 ± 0.1187 |
| Leukocytes, n=46, 52 | -0.69 ± 1.692 | -0.49 ± 1.947 |
Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate bilirubin, direct bilirubin and creatinine. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Micromole (UMOL)/ L | GSK2140944 1500 mg | GSK2140944 3000 mg |
|---|---|---|
| Bilirubin, n=52, 53 | -1.4 ± 5.42 | 0.4 ± 4.01 |
| Direct bilirubin, n=52, 53 | -0.2 ± 1.11 | 0.2 ± 1.45 |
| Creatinine, n=52, 53 | 1.38 ± 9.989 | 2.01 ± 7.737 |
Blood samples were collected at Baseline Day 1.(pre-dose) and at TOC visit (Day 4 to 8) to evaluate alanine aminotransferase, aspartate aminotransferase and alkaline phosphatase. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| International units (IU)/ L | GSK2140944 1500 mg | GSK2140944 3000 mg |
|---|---|---|
| Alanine Aminotransferase, n=52, 53 | 1.2 ± 7.24 | 1.8 ± 8.41 |
| Aspartate Aminotransferase, n=52, 53 | 2.0 ± 7.69 | 2.5 ± 8.69 |
| Alkaline Phosphatase, n=52, 53 | -1.8 ± 6.73 | -2.2 ± 6.26 |
Blood samples were collected at Baseline Day 1.(pre-dose) and at TOC visit (Day 4 to 8) to evaluate chloride, calcium, glucose, potassium, sodium and urea (blood urea nitrogen). Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Millimole (MMOL)/L | GSK2140944 1500 mg | GSK2140944 3000 mg |
|---|---|---|
| Chloride, n=52, 53 | 0.7 ± 2.02 | 0.3 ± 1.92 |
| Calcium, n=52, 53 | -0.017 ± 0.0869 | -0.047 ± 0.0874 |
| Glucose, n=52, 53 | -0.18 ± 1.184 | -0.02 ± 0.959 |
| Potassium, n=52, 53 | 0.04 ± 0.359 | -0.01 ± 0.355 |
| Sodium, n=52, 53 | 0.1 ± 2.28 | -0.1 ± 1.95 |
| Urea, n=52, 53 | 0.07 ± 1.098 | 0.04 ± 1.228 |
Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate erythrocytes (red blood cell count). Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| 10^12/L | GSK2140944 1500 mg | GSK2140944 3000 mg |
|---|---|---|
| Change From Baseline in Erythrocytes at Test-of-Cure Visit (Day 4 to 8) | -0.10 ± 0.227 | -0.15 ± 0.338 |
Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate erythrocytes mean corpuscular hemoglobin. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC Visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Picograms | GSK2140944 1500 mg | GSK2140944 3000 mg |
|---|---|---|
| Change From Baseline in Erythrocytes Mean Corpuscular Hemoglobin at Test-of-Cure Visit (Day 4 to 8) | 0.08 ± 0.457 | 0.12 ± 0.461 |
Blood samples were collected at Baseline Day 1 (pre-dose) and at TOC visit (Day 4 to 8) to evaluate erythrocytes mean corpuscular volume. Baseline was defined as the study assessment on Day 1 (pre-dose). Change from Baseline was calculated as value obtained at TOC Visit minus value at Baseline. Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Femtoliters | GSK2140944 1500 mg | GSK2140944 3000 mg |
|---|---|---|
| Change From Baseline in Erythrocytes Mean Corpuscular Volume at Test-of-Cure Visit (Day 4 to 8) | -0.3 ± 1.85 | -0.2 ± 1.71 |
Dipstick urinalysis was done for glucose, ketones, occult blood, protein, potential hydrogen (pH) and specific gravity at Baseline visit Day 1 (pre-dose) and Test-of-Cure visit (Day 4 to 8). Results were presented as negative (normal) or other findings reported only if observed under microscopic examination trace, 1+, 2+, 3+, 4+ and 5+ glucose, ketones, occult blood and protein. pH results were categorized as per their pH values. Baseline was defined as the study assessment on Day 1 (pre-dose). Only those participants available at the specified time points were analyzed (represented by n=X, X in the category titles).
| Participants | GSK2140944 1500 mg | GSK2140944 3000 mg |
|---|---|---|
| Glucose, pre-dose, Day 1, negative, n=50, 53 | 48 | 53 |
| Glucose, pre-dose, Day 1, trace, n=50, 53 | 1 | 0 |
| Glucose, pre-dose, Day 1, 1+, n=50, 53 | 0 | 0 |
| Glucose, pre-dose, Day 1, 2+, n=50, 53 | 0 | 0 |
| Glucose, pre-dose, Day 1, 3+, n=50, 53 | 1 | 0 |
| Glucose, pre-dose, Day 1, 4+, n=50, 53 | 0 | 0 |
| Glucose, pre-dose, Day 1, 5+, n=50, 53 | 0 | 0 |
| Glucose, Day 4 to 8, negative, n=48, 53 | 47 | 53 |
| Glucose, Day 4 to 8, trace, n=48, 53 | 0 | 0 |
| Glucose, Day 4 to 8, 1+, n=48, 53 | 0 | 0 |
| Glucose, Day 4 to 8, 2+, n=48, 53 | 0 | 0 |
| Glucose, Day 4 to 8, 3+, n=48, 53 | 1 | 0 |
| Glucose, Day 4 to 8, 4+, n=48, 53 | 0 | 0 |
| Glucose, Day 4 to 8, 5+, n=48, 53 | 0 | 0 |
| Ketones, pre-dose, Day 1, negative, n=50, 53 | 48 | 49 |
| Ketones, pre-dose, Day 1, trace, n=50, 53 | 2 | 3 |
| Ketones, pre-dose, Day 1, 1+, n=50, 53 | 0 | 1 |
| Ketones, pre-dose, Day 1, 2+, n=50, 53 | 0 | 0 |
| Ketones, pre-dose, Day 1, 3+, n=50, 53 | 0 | 0 |
| Ketones, pre-dose, Day 1, 4+, n=50, 53 | 0 | 0 |
| Ketones, pre-dose, Day 1, 5+, n=50, 53 | 0 | 0 |
| Ketones, Day 4 to 8, negative, n=48, 53 | 45 | 48 |
| Ketones, Day 4 to 8, trace, n=48, 53 | 3 | 4 |
| Ketones, Day 4 to 8, 1+, n=48, 53 | 0 | 1 |
| Ketones, Day 4 to 8, 2+, n=48, 53 | 0 | 0 |
| Ketones, Day 4 to 8, 3+, n=48, 53 | 0 | 0 |
| Ketones, Day 4 to 8, 4+, n=48, 53 | 0 | 0 |
| Ketones, Day 4 to 8, 5+, n=48, 53 | 0 | 0 |
| Occult blood, pre-dose, Day 1, negative, n=50, 53 | 35 | 42 |
| Occult blood, pre-dose, Day 1, trace, n=50, 53 | 6 | 4 |
| Occult blood, pre-dose, Day 1, 1+, n=50, 53 | 6 | 7 |
| Occult blood, pre-dose, Day 1, 2+, n=50, 53 | 2 | 0 |
| Occult blood, pre-dose, Day 1, 3+, n=50, 53 | 1 | 0 |
| Occult blood, pre-dose, Day 1, 4+, n=50, 53 | 0 | 0 |
| Occult blood, pre-dose, Day 1, 5+, n=50, 53 | 0 | 0 |
| Occult blood, Day 4 to 8, negative, n=48, 53 | 45 | 49 |
| Occult blood, Day 4 to 8, trace, n=48, 53 | 0 | 0 |
| Occult blood, Day 4 to 8, 1+, n=48, 53 | 1 | 1 |
| Occult blood, Day 4 to 8, 2+, n=48, 53 | 2 | 0 |
| Occult blood, Day 4 to 8, 3+, n=48, 53 | 0 | 3 |
| Occult blood, Day 4 to 8, 4+, n=48, 53 | 0 | 0 |
| Occult blood, Day 4 to 8, 5+, n=48, 53 | 0 | 0 |
| Protein, pre-dose, Day 1, negative, n=50, 53 | 37 | 39 |
| Protein, pre-dose, Day 1, trace, n=50, 53 | 8 | 9 |
| Protein, pre-dose, Day 1, 1+, n=50, 53 | 4 | 5 |
| Protein, pre-dose, Day 1, 2+, n=50, 53 | 1 | 0 |
| Protein, pre-dose, Day 1, 3+, n=50, 53 | 0 | 0 |
| Protein, pre-dose, Day 1, 4+, n=50, 53 | 0 | 0 |
| Protein, pre-dose, Day 1, 5+, n=50, 53 | 0 | 0 |
| Protein, Day 4 to 8, negative, n=48, 53 | 42 | 43 |
| Protein, Day 4 to 8, trace, n=48, 53 | 4 | 7 |
| Protein, Day 4 to 8, 1+, n=48, 53 | 2 | 2 |
| Protein, Day 4 to 8, 2+, n=48, 53 | 0 | 1 |
| Protein, Day 4 to 8, 3+, n=48, 53 | 0 | 0 |
| Protein, Day 4 to 8, 4+, n=48, 53 | 0 | 0 |
| Protein, Day 4 to 8, 5+, n=48, 53 | 0 | 0 |
| pH, pre-dose, Day 1, pH 5, n=50, 53 | 2 | 1 |
| pH, pre-dose, Day 1, pH 5.5, n=50, 53 | 5 | 8 |
| pH, pre-dose, Day 1, pH 6, n=50, 53 | 13 | 8 |
| pH, pre-dose, Day 1, pH 6.5, n=50, 53 | 12 | 14 |
| pH, pre-dose, Day 1, pH 7, n=50, 53 | 12 | 14 |
| pH, pre-dose, Day 1,pH 7.5 ,n=50, 53 | 4 | 7 |
| pH, pre-dose, Day 1, pH 8, n=50, 53 | 2 | 1 |
| pH, Day 4 to 8, pH 5, n=48, 53 | 0 | 0 |
| pH, Day 4 to 8, pH 5.5, n=48, 53 | 10 | 11 |
| pH, Day 4 to 8, pH 6, n=48, 53 | 13 | 15 |
| pH, Day 4 to 8, pH 6.5, n=48, 53 | 9 | 14 |
| pH, Day 4 to 8, pH 7, n=48, 53 | 10 | 7 |
| pH, Day 4 to 8, pH 7.5, n=48, 53 | 5 | 3 |
| pH, Day 4 to 8, pH 8, n=48, 53 | 1 | 3 |
Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from start of the study treatment (Day1) until Test-of-Cure visit (Day 4 to 8).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| GSK2140944 1500 mg | — | 0/52 (0%) | 22/52 (42.3%) |
| GSK2140944 3000 mg | — | 0/53 (0%) | 28/53 (52.8%) |
| Event | GSK2140944 1500 mg | GSK2140944 3000 mg |
|---|---|---|
| DiarrhoeaGastrointestinal disorders | 9/52 | 19/53 |
| FlatulenceGastrointestinal disorders | 14/52 | 10/53 |
| NauseaGastrointestinal disorders | 3/52 | 11/53 |
| Abdominal painGastrointestinal disorders | 6/52 | 10/53 |
| DizzinessNervous system disorders | 1/52 | 6/53 |
| HyperhidrosisSkin and subcutaneous tissue disorders | 1/52 | 6/53 |
| FatigueGeneral disorders | 3/52 | 5/53 |
| Abdominal discomfortGastrointestinal disorders | 4/52 | 2/53 |
| Feeling hotGeneral disorders | 1/52 | 4/53 |
| EructationGastrointestinal disorders | 1/52 | 3/53 |
| Age, Continuous(Years) | GSK2140944 1500 mg | GSK2140944 3000 mg | Total |
|---|---|---|---|
| Mean | 34.1 ± 11.45 | 32.4 ± 11.33 | 33.3 ± 11.37 |
| Sex: Female, Male(Participants) | GSK2140944 1500 mg | GSK2140944 3000 mg | Total |
|---|---|---|---|
| Female | 3 | 2 | 5 |
| Male | 50 | 51 | 101 |
| Race/Ethnicity, Customized(Participants) | GSK2140944 1500 mg | GSK2140944 3000 mg | Total |
|---|---|---|---|
| African American/African Heritage (Heri.) | 22 | 25 | 47 |
| American Indian or Alaska Native | 1 | 1 | 2 |
| Central/South Asian Heritage | 0 | 1 | 1 |
| Japanese/East Asian Heri. /South East Asian Heri. | 1 | 0 | 1 |
| Native Hawaiian or other Pacific Islander | 0 | 1 | 1 |
| White | 24 | 21 | 45 |
| White & African American/African Heritage | 0 | 1 | 1 |
| Unknown | 5 | 3 | 8 |
The record gives a start of Apr 2015, a primary completion of Jul 2016 and a completion of Jul 2016. It does not say whether these dates are actual or estimated.
Results were first posted in May 2017, 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Gepotidacin